{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:05:35Z","timestamp":1769756735596,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"am","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.revmed.2020.10.384","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T08:53:21Z","timestamp":1605603201000},"page":"134-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Syndrome TAFRO et vascularite n\u00e9crosante cutan\u00e9e\u00a0: une association in\u00e9dite"],"prefix":"10.1016","volume":"42","author":[{"given":"J.","family":"Maquet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Bories","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.B.","family":"Nogier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Aizel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Toledano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Faguer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Paricaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Pugnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Moulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Astudillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Sailler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2020.10.384_bib0155","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12185-019-02780-1","article-title":"2019\u00a0Updated diagnostic criteria and disease severity classification for TAFRO syndrome","volume":"111","author":"Japanese","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.revmed.2020.10.384_bib0160","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/JBM.S127822","article-title":"TAFRO syndrome: current perspectives","volume":"9","author":"Sakashita","year":"2018","journal-title":"J Blood Med"},{"key":"10.1016\/j.revmed.2020.10.384_bib0165","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.2169\/internalmedicine.2717-19","article-title":"Subclinical Hypothyroidism in TAFRO Syndrome","volume":"58","author":"Oka","year":"2019","journal-title":"Intern Med Tokyo Jpn"},{"key":"10.1016\/j.revmed.2020.10.384_bib0170","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.24242","article-title":"Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease","volume":"91","author":"Iwaki","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2020.10.384_bib0175","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s12185-016-1979-1","article-title":"Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015\u00a0version","volume":"103","author":"Masaki","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.revmed.2020.10.384_bib0180","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3960\/jslrt.19021","article-title":"Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan","volume":"59","author":"Masaki","year":"2019","journal-title":"J Clin Exp Hematop JCEH"},{"key":"10.1016\/j.revmed.2020.10.384_bib0185","first-page":"320","article-title":"[Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly]","volume":"51","author":"Takai","year":"2010","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.revmed.2020.10.384_bib0190","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/1066896908315812","article-title":"Clinical implications of idiopathic multicentric castleman disease among Japanese: a report of 28\u00a0cases","volume":"16","author":"Kojima","year":"2008","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.revmed.2020.10.384_bib0195","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3960\/jslrt.53.57","volume":"53","author":"Kawabata","year":"2013","journal-title":"J Clin Exp Hematop JCEH"},{"key":"10.1016\/j.revmed.2020.10.384_bib0200","doi-asserted-by":"crossref","first-page":"42316","DOI":"10.1038\/srep42316","article-title":"Elevated serum interferon \u03b3-induced protein 10kDa is associated with TAFRO syndrome","volume":"7","author":"Iwaki","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.revmed.2020.10.384_bib0205","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.25554","article-title":"Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?","volume":"94","author":"Fujimoto","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2020.10.384_bib0210","doi-asserted-by":"crossref","first-page":"152563","DOI":"10.1016\/j.prp.2019.152563","article-title":"The potential role of follicular helper T cells in idiopathic multicentric Castleman disease with and without TAFRO syndrome","volume":"215","author":"Kurose","year":"2019","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.revmed.2020.10.384_bib0215","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1038\/s41388-020-1204-9","article-title":"Genetic basis for iMCD-TAFRO","volume":"39","author":"Yoshimi","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.revmed.2020.10.384_bib0220","doi-asserted-by":"crossref","first-page":"e11045","DOI":"10.1097\/MD.0000000000011045","article-title":"Successful treatment with tacrolimus in TAFRO syndrome: two case reports and literature review","volume":"97","author":"Shirai","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.revmed.2020.10.384_bib0225","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/pin.12856","article-title":"Hepatic Campylobacter jejuni infection in patients with Castleman-Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome)","volume":"69","author":"Kageyama","year":"2019","journal-title":"Pathol Int"},{"key":"10.1016\/j.revmed.2020.10.384_bib0230","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3389\/fimmu.2019.01489","article-title":"Renal Pathologic Findings in TAFRO Syndrome: is there a continuum between thrombotic microangiopathy and membranoproliferative glomerulonephritis? A case report and literature review","volume":"10","author":"Leurs","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.revmed.2020.10.384_bib0235","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s12185-016-2025-z","article-title":"syndrome with reversible cardiomyopathy successfully treated with combination chemotherapy","volume":"104","author":"Yasuda","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.revmed.2020.10.384_bib0240","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2177\/jsci.39.64","article-title":"Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy","volume":"39","author":"Hiramatsu","year":"2016","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"10.1016\/j.revmed.2020.10.384_bib0245","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/ajh.24015","article-title":"Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome","volume":"90","author":"Jain","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2020.10.384_bib0250","first-page":"350","article-title":"[Efficacy of rituximab for TAFRO syndrome, a variant type of multicentric Castleman's disease]","volume":"55","author":"Ozawa","year":"2014","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.revmed.2020.10.384_bib0255","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5414\/CNCS109400","article-title":"Successful rituximab treatment of TAFRO syndrome with pathological findings of glomerular endothelial damage","volume":"6","author":"Noda","year":"2018","journal-title":"Clin Nephrol Case Stud"},{"key":"10.1016\/j.revmed.2020.10.384_bib0260","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2169\/internalmedicine.55.4710","article-title":"Successful Treatment with Cyclosporin A in Tocilizumab-resistant TAFRO Syndrome","volume":"55","author":"Yamaga","year":"2016","journal-title":"Intern Med Tokyo Jpn"},{"key":"10.1016\/j.revmed.2020.10.384_bib0265","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1158\/1535-7163.MCT-10-0156","article-title":"Successful Treatment of Castleman's Disease with Interleukin-1\u00a0Receptor Antagonist (Anakinra)","volume":"9","author":"El-Osta","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.revmed.2020.10.384_bib0270","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.critrevonc.2018.05.015","article-title":"Tafro syndrome: critical review for clinicians and pathologists","volume":"128","author":"Paydas","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.revmed.2020.10.384_bib0275","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1468-3083.2006.01941.x","article-title":"Urticarial vasculitis and Castleman's disease","volume":"21","author":"Alizadeh","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.revmed.2020.10.384_bib0280","first-page":"305","article-title":"Multicentric plasma cell variant Castleman's disease presenting with cutaneous vasculitis and pulmonary parenchymal involvement in a patient with ankylosing spondylitis: case report and review of the literature","volume":"66","author":"Wolf","year":"2011","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.revmed.2020.10.384_bib0285","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-018-0009-4","article-title":"Cryoglobulinaemia","volume":"4","author":"Roccatello","year":"2018","journal-title":"Nat Rev Dis Primer"},{"key":"10.1016\/j.revmed.2020.10.384_bib0290","first-page":"142","article-title":"Cryofibrinogenemia","volume":"19","author":"Michaud","year":"2013","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"key":"10.1016\/j.revmed.2020.10.384_bib0295","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40257-016-0228-y","article-title":"Cryofibrinogenemia-induced cutaneous ulcers: a review and diagnostic criteria","volume":"18","author":"Grada","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.revmed.2020.10.384_bib0150","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.amjmed.2015.03.009","article-title":"Cryofibrinogenemia: a marker of severity of cryoglobulinemic vasculitis","volume":"128","author":"Michaud","year":"2015","journal-title":"Am J Med"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866320307797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866320307797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:43:03Z","timestamp":1759336983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866320307797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0248866320307797"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2020.10.384","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Syndrome TAFRO et vascularite n\u00e9crosante cutan\u00e9e\u00a0: une association in\u00e9dite","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2020.10.384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}